Constitutive photomorphogenesis 9 (COP9) signalosome 5 (CSN5), an isopeptidase that removes neural precursor cell-expressed, developmentally down-regulated 8 (NEDD8) moieties from cullins (thus termed "deNEDDylase") and a subunit of the cullin-RING E3 ligase-regulating COP9 signalosome complex, attenuates proinflammatory NF-κB signaling. We previously showed that CSN5 is up-regulated in human atherosclerotic arteries. Here, we investigated the role of CSN5 in atherogenesis in vivo by using mice with myeloidspecific Csn5 deletion. Genetic deletion of Csn5 in Apoe −/− mice markedly exacerbated atherosclerotic lesion formation. This was broadly observed in aortic root, arch, and total aorta of male mice, whereas the effect was less pronounced and site-specific in females. Mechanistically, Csn5 KO potentiated NF-κB signaling and proinflammatory cytokine expression in macrophages, whereas HIF-1α levels were reduced. Inversely, inhibition of NEDDylation by MLN4924 blocked proinflammatory gene expression and NF-κB activation while enhancing HIF-1α levels and the expression of M2 marker Arginase 1 in inflammatory-elicited macrophages. MLN4924 further attenuated the expression of chemokines and adhesion molecules in endothelial cells and reduced NF-κB activation and monocyte arrest on activated endothelium in vitro. In vivo, MLN4924 reduced LPS-induced inflammation, favored an antiinflammatory macrophage phenotype, and decreased the progression of early atherosclerotic lesions in mice. On the contrary, MLN4924 treatment increased neutrophil and monocyte counts in blood and had no net effect on the progression of more advanced lesions. Our data show that CSN5 is atheroprotective. We conclude that MLN4924 may be useful in preventing early atherogenesis, whereas selectively promoting CSN5-mediated deNEDDylation may be beneficial in all stages of atherosclerosis.
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A therosclerosis is the primary cause of cardiovascular diseases. As a chronic inflammatory condition of the vessel wall, atherosclerosis is characterized by endothelial cell activation resulting in the secretion of chemoattractant proteins such as CCL2 and macrophage migration inhibitory factor (MIF) and by increased expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). These molecules synergize to sequentially recruit inflammatory cells such as monocytes and T lymphocytes into the vessel wall (1) (2) (3) .
The transcription factor NF-κB plays a crucial role in vascular inflammation and atherogenesis, e.g., by controlling the expression of inflammatory cytokines, chemokines, and adhesion molecules that orchestrate the recruitment and adhesion of leukocytes. Also, numerous genes that regulate differentiation, survival, and proliferation of vascular and immune cells involved in the inflammatory response are targets of NF-κB (4) . In resting cells, the NF-κB dimer, p65 and p50, is inactivated by binding to the inhibitor of κB (IκB)-α protein. Inflammatory challenges such as LPS or TNF-α exposure trigger the phosphorylation of IκB-α by the IKK complex (5) and its polyubiquitination by the cullin-RING E3 ubiquitin ligase (CRL) S-phase kinase-associated protein 1 (SKP1)-CUL1/RBX1-βTrCP CRL (SCF βTrCP ), containing cullin-1 (CUL-1) and RING protein ring-box 1 (RBX1) as the enzymatic core, SKP1 as an adaptor, and the β-transducin repeatcontaining protein (βTrCP) as substrate-binding F-box protein (6) .
Significance
Atherosclerosis is an inflammatory condition of the artery wall and main cause of myocardial infarction and stroke. Inflammatory processes evoking atherogenic lesions involve NF-κB-dependent endothelial-cell activation and monocyte/macrophage recruitment. Constitutive photomorphogenesis 9 (COP9) signalosome (CSN) subunit 5 (CSN5) and the CSN control cullin/RING E3 ligasedependent degradation of cell-cycle regulators and inhibitor of κB-α by cleaving neural precursor cell-expressed, developmentally down-regulated-8 (NEDD8) from cullins. CSN5 promotes tumorigenesis in humans. We generated a conditional KO mouse in which macrophage/granulocyte-CSN5 is deleted. We show that CSN5 suppresses macrophage inflammation and that mice lacking myeloid CSN5 develop larger atherosclerotic lesions. The NEDDylation inhibitor MLN4924 attenuates early atherosclerosis and inhibits inflammation in macrophages and endothelial cells. With MLN4924 in clinical trials, deNEDDylation approaches may qualify as therapeutics to reduce early-stage atherogenesis.
Ubiquitinated IκB-α is degraded, releasing the NF-κB dimer to drive gene transcription.
By using KO and transgenic models, differential roles of NF-κB at several stages in the atherogenic process have been demonstrated (7, 8) , suggesting that there is a complex and cell typespecific role of the canonical NF-κB pathway in atherosclerosis, which needs further investigation.
Activation of NF-κB depends on a number of control mechanisms, e.g., at the level of its inhibitor ΙκB-α. CRL-driven ΙκB-α ubiquitination is controlled by the constitutive photomorphogenesis 9 (COP9) signalosome complex (CSN). The CSN is a highly conserved, multifunctional protein complex of eight subunits (CSN1-CSN8), the 3D structure of which has recently been solved and which has sequence and structural homologies to the 19S lid subcomplex of the 26S proteasome (9, 10) . The CSN is involved in various cellular processes such as cell cycle control, DNA repair, and gene expression (11) . Catalyzed by the JAMM (JAB1-MPN-domain metalloenzyme) motif of CSN5 [also known as c-Jun activation domain binding protein-1 (JAB1)], a well-described enzymatic activity of the CSN is the cleavage of ubiquitin-like neural precursor cell-expressed developmentally downregulated 8 (NEDD8) conjugates from the cullin subunit of CRLs, including SCF-type CRLs (12, 13) . CSN5 is the only CSN subunit with catalytic activity and acts as part of the holocomplex and independently of the CSN (11) . Importantly, CSN5 has also been linked to inflammatory regulation (14) (15) (16) . Whereas the conjugation of NEDD8 to cullins, termed NEDDylation, is required for an optimal ubiquitin ligase activity of the SCFs (17) (18) (19) (20) , CSN-mediated deNEDDylation has been linked with the dissociation of the substrate-binding module from the SCF complex and with inhibition of SCF-mediated substrate ubiquitination in vitro (21, 22) . A multistep enzymatic process, involving the transfer of matured NEDD8 from a NEDD8-activating E1 onto a NEDD8-conjugating E2 enzyme and finally onto target proteins via an E3 ligase, governs NEDDylation (23) .
Inhibition of NEDDylation by the pharmacological agent MLN4924, which blocks E1 activity (24) , results in an increase of phosphorylated IκB-α (p-IκB-α) and consequently reduced NF-κB activation in B-cells, myeloid leukemia cells, macrophages, and endothelial cells (25) (26) (27) (28) . Similarly, signal-induced turnover of IκB-α was shown to be reduced by the deNEDDylating protein CSN5 in endothelial cells (29) and cervical cancer cells (30) , reducing NF-κB activation (29) . This stabilizing effect of CSN5 toward IκB-α in stimulated cells was explained by the association of the CSN with the deubiquitinase USP15 (30) and by CSN5-mediated deNEDDylation of cullins, controlling SCF activity (11) . Overall, MLN4924 and CSN5 both reduce NEDDylation and are involved in the regulation of NF-κB activation.
We recently observed that CSN5 is overexpressed in human atherosclerotic lesions, particularly in the endothelium, as well as in macrophage foam cells, upon atheroprogression (29) . We also reported that CSN5 negatively affected inflammatory processes in endothelial cells in vitro (29) , prompting us to speculate that CSN5 and deNEDDylation might have an atheroprotective function in vivo. Here, we tested this hypothesis and examined whether myeloid-born CSN5 and the cullin NEDDylation inhibitor MLN4924 were able to reduce atherosclerosis in vivo. Tables S1 and S2) .
Results

Myeloid
Myeloid-specific deletion of Csn5 in male mice resulted in markedly larger atherosclerotic lesions in the aortic root (Fig.  1A) , the aorta (Fig. 1B) , and the aortic arch ( No differences were observed in apoptosis, although the plaque necrotic core was significantly larger in the absence of Csn5 in myeloid cells (SI Appendix, Fig. S2 E and F) . Also, the number of proliferating macrophages per plaque area was not changed upon myeloid Csn5 deficiency (SI Appendix, Fig. S2G ). An increase in plaque size was also observed in the aorta, mainly in the abdominal aorta, of female Csn5 Δmyeloid /Apoe −/− mice, although it was less pronounced than in male mice (SI Appendix, Fig.  S3A ). Root lesions in female mice were not altered in size (SI Appendix, Fig. S3B ), indicating site-specific effects.
In conclusion, the atherosclerotic phenotype of the Csn5 genedeficient mice suggests that Csn5 attenuates atherosclerotic lesion formation in vivo.
Deficiency of Csn5 Promotes a Proinflammatory Profile in Macrophages.
As Csn5 deficiency increased the size of atherosclerotic lesions without affecting the lesional inflammatory cell content, we examined the effect of Csn5 deletion on the gene-expression profile of macrophages by using bone marrow-derived macrophages (BMDMs) from Csn5
Δmyeloid
/Apoe
−/− vs. Csn5 wt /Apoe −/− mice. There was an appreciable deletion of Csn5 (60-70%) on an mRNA and protein level (SI Appendix, Fig. S1 B and C), as reported for other LysM-Cre-driven deleted genes (31) . Csn5 deletion also affected levels of the CSN3 and CSN8 subunits of the CSN complex (SI Appendix, Fig. S1D ), indicating inactivation of the entire CSN complex. Surface expression of the macrophage marker F4/80 was not significantly changed upon Csn5 deficiency (SI Appendix, Fig. S1E ).
Csn5-deficient macrophages and WT controls were stimulated with the inflammatory reagent LPS for 0-24 h. Csn5 deletion led to a significant increase in Il-12 and Il-6 mRNA levels 6 and/or 24 h after LPS stimulation ( Fig. 2A) . Also, after 24 h, LPSinduced secretion of bioactive Il-12p70 was increased upon Csn5 deletion (Fig. 2B, Left) . Given our recent observation that CSN5 regulates the stability of IκB-α in human endothelial cells (29) , and as NF-κB activation is a trigger of inflammatory cytokine production in atherogenesis, we examined whether the effect on gene expression was associated with the NF-κB pathway. We noted a significant decrease in basal IκB-α levels upon Csn5 deletion. Also, the strong LPS-induced degradation rate of IκB-α was further enhanced by Csn5 deficiency at early time points (Fig. 2C) , indicating an increase in NF-κB activation in response to Csn5 deletion. Similar results were obtained when macrophages were treated with TNF-α, a relevant inflammatory stimulus in atherogenesis, with Csn5 deficiency enhancing TNF-α-induced Il12p70 secretion (Fig. 2B, Right) and NF-κB activation (Fig. 2D) . Furthermore, the NF-κB-regulating micro-RNAs (miRs) miR146a and mi-R21, both induced in macrophages upon LPS treatment, failed to be up-regulated in Csn5
Δmyeloid /Apoe −/− cells, with miR-21 significantly reduced in Csn5
Δmyeloid /Apoe −/− cells at 6 and 24 h after LPS stimulation compared with control. Csn5 deficiency did not ablate the induction of miR-155a upon LPS stimulation, while up-regulation was only slightly reduced compared with Csn5 wt /Apoe −/− controls (Fig. 2E) . The NF-κB-inhibitory protein A20 was not differentially regulated in WT and Csn5-deficient macrophages (SI Appendix, Fig. S4 ). These data suggest that, under inflammatory conditions, CSN5-regulated NF-κB activity is a critical mechanism contributing to the inhibitory effects of CSN5 on proinflammatory cytokine production in macrophages.
To further study the effect of Csn5 on proinflammatory macrophage cytokine profiles, we examined the chemokine-like cytokine MIF, which has been shown to drive atherosclerosis (3) and whose secretion is inhibited by CSN5 in endothelial and tumor cells (29, 32) . We observed an increased secretion of MIF in Csn5-deleted macrophages (Fig. 2F) . Moreover, in accord with prior observations that CSN5 stabilizes the transcription factor HIF-1α under normoxic and hypoxic conditions (33) , Csn5 deletion led to significantly decreased nuclear levels of HIF-1α upon LPS treatment (Fig. 2G) . A significant reduction was observed for the HIF-1α target genes (34) Edn1 and Opn1 upon Csn5-deletion in LPS-stimulated macrophages, whereas c-Met 
Csn5
Δmyeloid /Apoe −/− mice following culture for 24 h.
(G) HIF-1α was quantified in nuclear lysates from LPSstimulated (100 ng/mL, 6 h) cells or untreated control cells. HIF-1α levels were normalized to lamin B1. Representative Western blot is shown. Graphs represent means ± SD of three to six independent experiments, except E and F (n ≥ 6). Mann-Whitney test (F and G) and two-way ANOVA with Bonferroni posttest were performed for comparison between Csn5 wt /Apoe −/− and Csn5 Δmyeloid /Apoe −/− (asterisks) and stimulated vs. nonstimulated conditions of same genotype ( §; B-E; */ § P < 0.05; **/ § § P < 0.01; ***/ § § § P < 0.001).
and Ets1 were not significantly affected. Mmp9, which also is prominently controlled by NF-κB, was up-regulated in Csn5-KO inflammatory macrophages (SI Appendix, Fig. S5 ). In line with the lack of effect of Csn5 deficiency on plaque macrophage proliferation, BMDM proliferation in vitro was not significantly changed upon Csn5 deficiency (SI Appendix, Fig. S6A ). In conclusion, the deNEDDylating enzyme CSN5 represses inflammatory NF-κB activation and proinflammatory cytokine production in inflammatory macrophages, but also influences the HIF-1α pathway.
Inhibition of NEDDylation by MLN4924 Inhibits Macrophage Inflammatory
Responses. Whereas CSN5 induces deNEDDylation by cleaving NEDD8 conjugates from the cullin subunit of CRLs (13), the pharmacological inhibitor MLN4924 inhibits NEDDylation by inhibiting the NEDD8-activating enzyme E1 (NAE) (24) . Hence, MLN4924 activity, at least in part, mirrors effects afforded by the overexpression or up-regulation of CSN5, although additional MLN4924 effects may be expected as a result of non-cullin NEDDylation target proteins. Of note, MLN4924 was shown to be generally well tolerated in physiologically active doses in phase I clinical trials in patients with advanced nonhematological malignancies (35) and acute myeloid leukemia and myelodysplastic syndromes (28) . We reasoned that MLN4924-treated macrophages would produce less proinflammatory cytokines in inflammation. BMDMs were isolated from Apoe −/− mice and treated with MLN4924 or DMSO control solution. Differentiation of macrophages was not affected by MLN4924, as indicated by similar surface expression of the macrophage marker F4/80 (SI Appendix, Fig. S7A ). Treatment with MLN4924 inhibited cullin-1 NEDDylation (Fig. 3A and SI Appendix, Fig. S7B ) and resulted in a significant decrease of LPSinduced proinflammatory gene expression, attenuating the levels of Tnf-α, Il-6, and Il-12 after 6 h and those of Tnf-α, Il-6, Il-12, and Ccl2 after 24 h LPS stimulation (Fig. 3B ). Also, MLN4924 was able to inhibit basal gene expression of Tnf-α and Il-12 ( was repressed by MLN4924, whereas IL-10 production was unaffected (Fig. 3C) . LPS-induced activation of NF-κB was markedly inhibited by MLN4924, although basal NF-κB activation was not affected (Fig. 3D ). Although this is in line with MLN4924 targeting the NF-κB pathway, we also found that MLN4924 increased nuclear HIF-1α levels in inflammatory-elicited macrophages (Fig. 3E) , confirming the opposite effect seen in Csn5-deficient macrophages, and regulated MAPK signaling. MLN4924 decreased ERK1/2 and (in part) p38 phosphorylation in macrophages stimulated with LPS or TNF-α ( Fig. 3F and SI Appendix, Fig. S8 ). Macrophage proliferation, similar to what we observed upon Csn5 deficiency, was not influenced by MLN4924 (SI Appendix, Fig. S6B ). Together, these data indicate that inhibition of NEDDylation by MLN4924 inhibits the proinflammatory cytokine milieu in macrophages and interferes with NF-κB, HIF-1α, and MAPK signaling in these cells.
MLN4924 Polarizes Macrophages Toward an M2 Phenotype. Atherosclerotic plaques in humans and mice contain M1 and M2 macrophages (36, 37) . These subsets of macrophages have been studied extensively in vitro and in various mouse atherosclerosis models, leading to the simplified notion that M1 macrophages, as a result of their inflammatory characteristics, promote plaque inflammation, whereas M2 macrophages resolve it (38) . Our observation that MLN4924-treated macrophages expressed lower levels of the classical M1 cytokines (39) Tnf-α, Il-12, and Il-6, prompted us to consider a possible MLN4924-elicited macrophage switch from M1 to M2. To examine this, BMDMs isolated from Apoe −/− mice were treated with MLN4924 or DMSO control solvent and challenged with LPS as a surrogate inflammatory stimulus. In addition to the reduced expression of the M1 cytokines observed upon MLN4924 treatment ( Fig. 3 B  and C) , the antiinflammatory, M2-polarizing cytokine Il-13 and the M2 marker Arginase-1 were significantly up-regulated after 24 h of LPS exposure without significantly affecting the M1 marker iNos (Fig. 3G ). This indicates that MLN4924 skews macrophage polarization toward an antiinflammatory M2 state, even in the absence of exogenous, M2 polarizing cytokines such as IL-4.
MLN4924 Inhibits Proatherogenic Gene Expression, Monocyte Arrest, and NF-κB Activation in Inflammatory-Elicited Endothelial Cells. To investigate whether MLN4924 would also affect inflammatory processes in other cell types important in atherosclerosis, we tested its effect on the expression of proatherosclerotic proteins in primary endothelial cells. TNF-α strongly induced the gene expression of the chemokine CCL2 and the adhesion molecules VCAM-1 and ICAM-1 in human umbilical vein endothelial cells (HUVECs), human aortic endothelial cells (HAoECs), and mouse aortic endothelial cells (MAoECs), and MLN4924 treatment essentially completely inhibited these responses, except for CCL2 in MAoECs (Fig. 4A and SI Appendix, Fig. S9 A and B) . The adhesion molecule P-selectin was only moderately up-regulated in MAoECs (SI Appendix, Fig. S9B ), and was not at all up-regulated upon 4 or 8 h of TNF-α stimulation in HUVECs or HAoECs, yet MLN4924 further lowered P-selectin expression in both human endothelial cell types after 4 h of TNF-α treatment (Fig. 4A and SI Appendix, Fig. S9 A and B) , possibly implying an NF-κB-independent mechanism. Adhesion molecules and chemokines act in concert to mediate the arrest of monocytes on activated endothelium of an atherogenic vessel. We performed laminar flow adhesion assays applying resting and TNF-α-activated HUVECs. TNF-α-stimulated HUVECs showed a significant increase in the number of arrested monocytes, and this effect was completely ablated by MLN4924 treatment (Fig. 4B ).
We next directly tested whether the inhibitory effect of MLN4924 on atherogenic gene expression in primary endothelial cells was at least partly associated with reduced NF-κB signaling. MLN4924 treatment completely inhibited cullin-1 NEDDylation (SI Appendix, Fig. S7C ), and this coincided with the accumulation of phosphorylated IκB-α in HUVECs (Fig. 4C) as well as in HAoECs (SI Appendix, Fig. S9C ), indicating that inhibition of cullin-1 NEDDylation impairs the activity of SCF-driven ubiquitination processes. Next, we examined the activation of NF-κB upon MLN4924 preexposure. MLN4924-treated endothelial cells showed a complete inhibition in TNF-α-or LPS-induced NF-κB activation as determined by reporter gene assay ( Fig. 4D and SI Appendix, Fig. S10 ). As seen in macrophages, MLN4924 also strongly enhanced nuclear HIF-1α levels in LPS-stimulated endothelial cells (Fig. 4E) . Together, this indicates that MLN4924 interferes with inflammatory and atherogenic processes in endothelial cells, reflected in reduced atherogenic gene expression, NF-κB activation, and monocyte arrest, and accompanied by HIF-1α stabilization.
Inhibition of NEDDylation by MLN4924 Interferes with Early
Atherosclerotic Lesion Formation in Aorta and Root. We next investigated whether MLN4924 would reduce atherosclerosis in vivo, i.e., affecting atherosclerosis pathology opposite to the effect seen upon genetic deletion of the deNEDDylating enzyme Csn5.
To probe the effect of MLN4924 on existent atherosclerotic lesions, male Apoe −/− mice were exposed to a high-fat diet. After 6 wk, i.e., when early lesions had developed, thus representing a clinically relevant situation, mice were injected s.c. with 60 mg/kg MLN4924 or with a solvent control solution twice per day on 2 d per week for another 6 wk under continued diet. After a total of 12 wk of high-fat diet, the body weight of the mice, serum cholesterol, triglyceride, and alanine aminotransferase levels, the latter indicating the effect of the inhibitor on the liver, were analyzed and found to be comparable for both groups (SI Appendix, Table S3 ). Analysis of leukocyte subpopulations in blood revealed an increase in thrombocytes and innate immune cells, i.e., neutrophils and monocytes, in the MLN4924-treated group. Among the latter, Gr1 hi monocytes were significantly elevated, whereas the increase in the Gr1 low subpopulation in the MLN4924-treated group failed to reach statistical significance by a slight margin (Fig. 5A and SI Appendix, Table S3 ). At the same time, B-cell numbers were decreased, resulting in overall comparable total leukocyte counts (Fig. 5A) .
Quantification of lesions showed a significantly reduced lesion area in the descending aorta in the MLN4924-treated group, with MLN4924 treatment reversing atherosclerosis development in the aorta back to baseline levels (Fig. 5B) . In aortic root, MLN4924 treatment did not influence overall lesion size (Fig.  5C ). However, lesion classification (SI Appendix, Fig. S11A ) revealed that MLN4924 specifically reduced the size of early-to intermediate-stage lesions but not advanced lesions (Fig. 5D and SI Appendix, Fig. S11A ). No significant differences were observed in aortic arch (SI Appendix, Fig. S11 B-D) . Plaque characteristics in aortic root were examined next. Although no significant differences were observed in plaque macrophage and smooth muscle cell content, as well as necrotic core area or TUNEL + cell content, between MLN4924-vs. DMSO-treated animals (SI Appendix, Fig. S11 E and G-I), collagen content of root lesions was significantly reduced in the MLN4924-treated group (SI Appendix, Fig. S11F ).
In summary, our results indicate that treatment with MLN4924 attenuates the formation of early atherosclerotic lesions in descending aorta and aortic root, whereas more advanced lesions in aortic root or arch were not affected.
MLN4924 Reduces Inflammation in Vivo.
We then wished to further study the effect of MLN4924 on the inflammatory response in vivo. We first asked whether our in vitro finding that MLN4924 inhibits atherogenic protein expression in inflammatory endothelial cells and macrophages (Figs. 3 and 4) would be reflected in an in vivo setting. Apoe −/− mice fed a high-fat diet for 12 wk were s.c. injected, at halftime of the diet, with 60 mg/kg MLN4924 vs. control solvent twice per day on 2 d per week for 6 wk under continued diet. Serum levels of TNF-α (Fig. 6A) were significantly reduced in MLN4924-treated mice, whereas circulating antiinflammatory IL-10 ( Fig. 6A) A B and aortic Cxcl1 (P = 0.08) or aortic adhesion proteins were unaffected (SI Appendix, Fig. S12A ). We finally studied the in vivo effect of MLN4924 on the inflammatory response by interrogating its antiinflammatory capacity in LPS-induced inflammation in mice. MLN4924 pretreatment of mice injected i.p. with LPS strongly reduced serum levels of the inflammatory marker IL-6 ( Fig. 6 B and C), but not TNF-α and CCL2 (SI Appendix, Fig. S12B ). Peritoneal macrophages prepared from LPS-injected mice exhibited significantly decreased expression levels of Il-6 and Cxcl1 when isolated from MLN4924-treated vs. control mice, whereas antiinflammatory Il-10 was increased (Fig. 6D) . No significant differences were observed for Tnf-α, Ccl2, Il-12, or Arg-1 (Fig. 6D ).
In conclusion, these studies demonstrate that MLN4924 not only blocks early atherogenic lesion formation but also various inflammatory mediators known to govern inflammatory processes in vivo.
Discussion
We report on a role of the COP9 signalosome subunit 5 (i.e., CSN5) in attenuating atherogenesis in vivo. We also demonstrate that the pharmacological inhibitor MLN4924, a compound in phase I clinical trials for cancer and known to reduce protein NEDDylation, thereby mimicking CSN5 overexpression, inhibits early atherosclerotic lesion formation in aorta and aortic root as well as acute inflammation in vivo. Both CSN5 and MLN4924 inhibit inflammatory and proatherogenic gene expression through attenuation of NEDD8 conjugation to cullins, and our data suggest that this is, at least partly, the result of a marked negative regulation of the NF-κB pathway (SI Appendix, Fig. S13 ), with additional roles for MAPK signaling and modulation by HIF-1α.
Previous studies described the participation of CSN5 in NF-κB activation in epithelial and T cells (30, 40) . We recently extended this to endothelial cells and found CSN5 to attenuate TNF-α-triggered monocyte adhesion on endothelium in vitro. Additionally, we observed an overexpression of CSN5 and two other CSN subunits in atherosclerotic lesions of human carotid arteries upon atheroprogression, a first hint that the CSN may have a functional role in atherogenesis in vivo (29) . However, descriptive correlations and in vitro studies frequently cannot predict effects in a complex disease situation in vivo or exclude a bystander role.
Our study clearly reveals enhanced atherosclerotic lesion formation in hyperlipidemic mice lacking Csn5 in myeloid cells. The antiatherogenic role of CSN5 was more pronounced in male compared with female mice. Whereas Csn5 deficiency in males led to a broad increase in atherosclerotic lesions in aorta, root, and arch, strong lesion exacerbation in female mice was seen in only the abdominal aorta, with trends in thoracic aorta and aortic arch, whereas no effect was seen in root. Such sex-specific "intensity" effects on atherosclerosis have been reported before. For example, Cx3cl1 deficiency reduced aortic root lesion size in 12-wk-old female but not male mice, whereas Pctp deficiency increased atherosclerosis in male but not female mice (41) (42) (43) (44) (45) . Various molecular parameters including differences in lipid profiles, cellular responses to oxidized LDL, or NO-dependent endothelial dysfunction have been associated with sex-specific effects in atherosclerosis, but the mechanism has remained unclear in the majority of cases. Atherosclerotic lesions in our study were generally larger in female compared with male Apoe −/− mice, consistent with prior reports (46) . The more advanced plaques in females may partly confound atheroprotection by CSN5 in female mice. Also, there may be a CSN5-specific molecular basis for the less pronounced protective effect of CSN5 in females. CSN5/JAB1 was shown to interact with nuclear receptors, preferably progesterone, glucocorticoid, and estrogen receptor, and partially promotes the transactivation activity of these receptors (47).
Exacerbated atherosclerotic lesion formation upon Csn5 deficiency was not associated with a mere effect on lesional macrophage content, but was linked to inflammatory cytokine production in macrophages. Csn5-deficient macrophages exhibited an enhanced expression of inflammatory target genes such as Il-12 and Il-6. The role of IL-6 in atherosclerosis is ambivalent. In early atherosclerosis, IL-6 was found to augment the disease (48) , whereas Il-6-deficient mice developed more atherosclerosis in advanced stages (49) . In conjunction with our MLN4924 in vitro and in vivo data, these findings are in line with the preferential impairment of early vs. advanced atherogenic lesions by CSN5. IL-12 has a more unanimous role in atherosclerosis, with both gene targeting and blockade of IL-12 resulting in reduced atherosclerotic lesions in hyperlipidemic mice (50, 51) . Therefore, our observation that Csn5-deficient macrophages show an increased production of IL-12 may in part explain exacerbated atherosclerosis development in Csn5-KO mice.
As one possible underlying mechanism, Csn5-deficient macrophages exhibited a significant decrease in IκB-α levels and an increase in p65 activation, which is in line with reports using epithelial and endothelial cells (29, 30) . In support of this notion, Csn5-deficiency impaired LPS-induced up-regulation of the NF-κB-regulating miRs miR-146a and miR-21 in macrophages. MiR-146a targets TLR4, TRAF6, and IRAK1, thereby antagonizing NF-κB activation (52, 53) , and miR-21 was shown to negatively regulate NF-κB activity through PDCD4 (54) . Thus, decreased expression of these miRs contributes to the observed increase in LPS-induced NF-κB activation upon Csn5 deficiency. In accord, Csn5 deficiency decreased and MLN4924 stabilized HIF-1α in LPS-elicited macrophages (and endothelial cells). Both miR-146a and -21a expression levels are coregulated by HIF-1α (55, 56) . Decreased miR-21 and -146a levels in Csn5-deficient macrophages might thus in part be explained by reduced HIF-1α transcriptional activity. This furthers the conclusion that pathways other than NF-κB contribute to the phenotype seen in Csn5-deficient cells. Accordingly, not all genes analyzed in this study were up-regulated even though most are targets of NF-κB. This is in agreement with a prior study in which inhibition of NF-κB did not affect several well-described targets of NF-κB (31) . Also, some of the targets, i.e., CCL2, are additionally controlled by other promoter elements such as AP-1. Similarly, pathways influenced by alternative CRL substrates other than IκB-α may contribute to the observed effects in Csn5-deficient macrophages.
CSN5 leads to an enhancement of HIF-1α levels in inflammatory macrophages and endothelial cells, in accord with a role for CSN5 and NEDDylation in HIF-1α stabilization (33, 57, 58) . Although CSN5 has been suggested to stabilize HIF-1α in a CSN complex-, and thus NEDDylation-, independent manner, MLN4924 was proposed to stabilize HIF-1α, at least in mucosal inflammatory cells, via inhibition of NEDDylation of CUL2, the cullin component present within HIF-1α-ubiquitylating pVHL E3 ligase (59) . Given the role for HIF-1α in inflammatory gene expression (60), reduced nuclear HIF-1α may partly explain our finding that not all of the inflammatory genes studied were upregulated upon Csn5-deficiency. Similarly, the observation that not all HIF-responsive genes were decreased upon Csn5 KO in inflammatory macrophages may be partly explained by counteracting effects of NF-κB activation, e.g., for c-Met and Mmp9, which are regulated by HIF-1α as well as NF-κB (61) .
CSN5 has been reported to regulate the secretion of the inflammatory cytokine MIF (32) , which is strongly implicated in atherogenesis (3, 29) . Accordingly, Csn5-deficient macrophages secreted significant amounts of MIF compared with WT macrophages, despite unaltered Mif RNA levels, as expected for this nonclassically secreted mediator. This mechanism may further contribute to increased atherosclerosis in Csn5
Δmyeloid
/Apoe
−/− mice. Together, CSN5 inhibits atherosclerosis by broadly attenuating the production of proinflammatory and proatherogenic cytokines in macrophages. These processes involve regulation of NF-κB and HIF-1α signaling.
Recent reports described the NAE blocker MLN4924 as a potent inhibitor of NEDD8 conjugation of cullins (24) . We confirmed that MLN4924 treatment of macrophages and endothelial cells predominantly reduced NEDDylation of a cullin protein band. Cullin deNEDDylation reduces ubiquitin ligase activity of CRLs, consequently increasing the stability and transcriptional activity of CRL substrates such as IκB-α or HIF-1α (25, 59) . Because of its potential to fine-tune the NF-κB response, and also processes related to cell cycle control or DNA repair by regulating additional CRL targets such as β-catenin, p27, or CDT1, MLN4924 has been successfully used in animal tumor models and is in clinical trials for treatment of leukemia (24, 27, 62) . It was shown to be well tolerated in physiologically active doses in phase I clinical trials in patients with advanced nonhematological malignancies (35) , acute myeloid leukemia, and myelodysplastic syndromes (28) .
Here, we examined the effect of MLN4924 treatment on atherosclerosis in a relevant in vivo mouse model and observed a significant reduction in atherosclerotic lesion size in the aorta and early lesions of aortic root in response to this inhibitor. This was associated with a switch in monocyte-derived macrophages from a pro-to an antiinflammatory phenotype, as indicated by an increase in expression of the M2 macrophage marker Arginase-1 and the M2-polarizing cytokine Il-13 in MLN4924-treated macrophages isolated from Apoe −/− mice (63) . In addition Tnf-α, Il-12, Il-6, and Ccl2 expression levels were strongly reduced, indicating that macrophages in the MLN4924-treated group produce less inflammatory cytokines. A similar although not identical antiinflammatory phenotype was observed in an in vivo setting when studying macrophages prepared from LPS-injected mice cotreated with MLN4924, with antiinflammatory Il-10 strongly elevated and proinflammatory cytokines Il-6 and Cxcl1 attenuated, whereas markers such as Tnf-α and Il-12 were unchanged. An overall M2/antiinflammatory-polarizing role for MLN4924 is in accord with a recent study revealing that MLN4924 reduces inflammasome-dependent caspase-1 activation in macrophages (64) . The inflammasome controls IL-1β secretion, a process typical for M1 (65) but not M2 macrophages (66) . Atherosclerotic plaques in humans and mice contain M1 and M2 macrophages (36, 37) , and numerous atherosclerosis studies have led to the notion that M1 macrophages promote, whereas M2 macrophages resolve, plaque inflammation (38) . Thus, our observation that MLN4924 skews macrophages toward an antiinflammatory/M2 state in vitro and in vivo may at least partially explain the reduced atherosclerotic lesion size in aorta and early root lesions in MLN-treated mice.
MLN4924 inhibited basal gene expression of Tnf-α and Il-12 in macrophages even though basal NF-κB was not affected. This may indicate the involvement of other transcription factors and pathways regulating Tnf-α and Il-12 expression, which may also be regulated by NEDDylation and/or MLN4924. In fact, we found that MLN4924 stabilizes LPS-induced HIF-1α levels, and this effect was in line with observed decreased HIF-1α levels in Csn5-deficient cells. Also, MLN4924 reduced MAPK signaling in inflammatory-elicited macrophages. These data are in accord with reports of MLN4924 effects on HIF-1α stabilization in microvascular endothelial cells (26) and MAPK activation in T cells, the latter linked to MLN-induced stabilization of SHC, a negative regulator of ERK signaling that was identified as a target for NEDDylation (67) . Interestingly, the pathways identified in our study to be affected by MLN are linked with each other, e.g., reduced NF-κB activity, as observed upon MLN4924, was inversely linked with M2 polarization (68) , and Arginase-1 has been reported to be regulated by HIF-2α (69), which is stabilized by NEDDylation (58).
Our in vitro data add further mechanistic evidence. MLN4924-treated TNF-α-activated endothelial cells express overwhelmingly less CCL2, ICAM-1, and VCAM-1, which may at least partly be explained by reduced NF-κB activation. Interestingly, P-selectin was found to be reduced in MLN4924-treated human endothelial cells following 4 h of TNF-α stimulation, although upregulation by TNF-α per se did not reach significance. This is in line with previous reports showing that human P-selectin lacks canonical NF-κB binding sites and is not up-regulated in inflammation (70, 71) . A preference for MLN4924 to reduce ICAM-1 and VCAM-1 but not P-selectin levels is consistent with our observation that it markedly reduced monocyte arrest on endothelium. As mentioned, MLN4924 increases LPSinduced HIF-1α levels in endothelial cells, which corresponds with a previous observation of increased HIF activity in the kidney of LPS-treated mice (26) . Interestingly, endothelial HIF-1α had been found to promote atherosclerosis and enhance leukocyte adhesion, and myeloid HIF-1α was seen to promote or not affect atherosclerotic lesion formation (60, 72, 73) . With respect to our study, this could imply that increased HIF-1α may begin to counteract initial NF-κB-associated atheroprotective effects of MLN4924 implicated in early atherosclerosis and explain the absence of atheroprotection in more advanced lesions. A protective role for MLN4924 in early atherogenesis and endothelial dysfunction is supported by the notion that this compound improves endothelial barrier integrity and disturbed flow/ oxidized lipoprotein-elicited NEDDylation-dependent endothelial dysfunction (26, 74) .
Importantly, the observed antiinflammatory/antiatherogenic effect of MLN4924 on macrophages and endothelial cells corresponds to its function in vivo. MLN reduced the expression of proinflammatory cytokines in serum of hyperlipidemic and LPStreated mice. Moreover, MLN reduced the proinflammatory markers Il-6 and Cxcl1 in LPS-induced peritoneal macrophages in vivo, whereas Il-10 was increased. The observation that MLN4924-treated mice only showed a trend toward downregulation of the arrest chemokine Cxcl1 or adhesion markers in aortic tissue after 12 wk of high-fat diet might be explained by a counteracting, inducing, effect of endothelial HIF-1α on Cxcl1 (and other genes), as observed previously in the context of atherosclerosis (73) . In fact, our aortic gene expression analysis was performed in late-stage atherosclerosis, when HIF-1α effects may have penetrated to partially override the reduction of NF-κB activation by MLN4924. This notion is supported by our finding that MLN4924 reduced only early atherosclerotic lesions in the aorta and aortic root, but not advanced lesions. Predominant antiatherogenic activity by MLN4924 in early lesions may be the result of disease stage or site specificity, as induced by differences in flow stress at distinct anatomical locations (41) . Also, endothelial permeability changes are among the earliest hallmarks of atherosclerosis (2) . Thus, barrier function may have already been compromised when MLN treatment was started after 6 wk of Western diet. This might facilitate the influence of circulating Gr1 high monocytes or neutrophils, which were elevated upon MLN4924 treatment and may have overcompensated for the early-stage antiinflammatory effects of MLN4924 on endothelium. Such a scenario would be in line with data showing that atherosclerotic lesion size correlates with the number of circulating monocytes (75) and neutrophils (76) . Moreover, a selective expansion of myeloid cells paralleled by a decrease in lymphocytes as observed upon MLN treatment of hypercholesterolemic Apoe −/− mice was observed before in the context of atherosclerosis and inflammation (77) , and may be explained by a competition between granulo-and lymphopoiesis in a common bone marrow niche (78) or by PU1 activity, which is up-regulated by MLN and drives monocyte differentiation (79) .
One reason that Csn5 deficiency does not fully inversely phenocopy effects obtained by MLN4924 treatment might be because the drug was only administered for the last 6 wk of the diet whereas Csn5
Δmyeloid /Apoe −/− mice carried a constitutive deletion of Csn5 in myeloid cells throughout the entire period. MLN might also have effects independent of CSN-mediated pathways. For example, the target spectrum affected by MLNinduced hypoNEDDylation could be broader than that targeted by selective inhibition of CSN5. Such a notion is supported by the broader spectrum of genes affected by MLN4924 treatment compared with Csn5
Δmyeloid deficiency. It is also conceivable that the spectrum of NEDDylated cullins targeted by MLN4924 and CSN5 differs in relevant atherogenic cell types, affecting different CRL complexes. On the contrary, it is intriguing that MLN4924 treatment (inducing cullin hypoNEDDylation) and CSN inactivation by Csn5-gene deficiency (inducing cullin hyperNEDDylation) show the expected opposite effects on NF-κB activity. Previous results indicated in vivo SCF activity to be decreased by CSN overactivation and by complete CSN inactivation, both representing scenarios in which the activity of CRL complexes is compromised (11) (SI Appendix, Fig. S13 ). This may explain why Csn5-deficient thymocytes showed reduced steady-state NF-κB activity (40) .
With respect to CSN5, the clearness of the identified antiatherogenic (and antiinflammatory) effects is remarkable, as previous studies have also linked CSN5 to proinflammatory JNK/ AP1 signaling and proatherogenic LFA-1 integrin activation while counteracting inflammatory MIF activity (14) (15) (16) . This may be the result of COP9 complex-associated vs. complexindependent activities.
Together, our findings suggest a marked antiatherogenic effect of the deNEDDylation factor CSN5 in myeloid cells in vivo, as well as for the NEDDylation inhibitor MLN4924 in early atherosclerosis, by attenuating inflammatory mechanisms driving atherogenesis. This may argue for novel CSN-related therapies to specifically enhance CSN5 activation, e.g., based on a recently identified molecular trigger implicated in the active/inactive switch of CSN5's isopeptidase activity (80) . The observed atheroprotective effect of MLN4924 in early atherosclerosis should stimulate studies to investigate its impact in injury-induced restenosis, in which reendothelialization is a key mechanism to reduce neointimal hyperplasia.
Materials and Methods
Detailed study methods are provided in SI Appendix.
Animal Models. C57BL/6 LysM-Cre/Csn5 flox/flox mice were crossed with atherosclerosis-prone C57BL/6 Apoe −/− mice to obtain a myeloid-specific deletion of Csn5 on Apoe −/− background. To study effects on atherosclerosis, male and female mice were given a high-fat diet for 12 wk, and size and composition of atherosclerotic lesions were assessed by histology and immunofluorescence. To examine the effect of MLN4924 on atherosclerosis, male Apoe −/− mice were fed a high-fat diet for 12 wk. After 6 wk, mice were injected s.c. with 60 mg/kg MLN4924 or control solvent twice per day on two days per week for another 6 wk under continued diet. After a total of 12 wk of diet, mice were killed for analysis of atherosclerosis and gene expression. Furthermore, Apoe −/− mice were injected i.p. with 15 mg/kg MLN4924 vs. control solvent twice per day for a total of 2 d. After 24 h, mice received an i.p. LPS injection (1 μg/mL). After 48 h, mice were killed, and peritoneal macrophages were isolated, adhered for 1 h, and subjected to gene expression analysis.
Cell Culture. HUVECs, HAoECs, MAoECs, and BMDMs were stimulated with 20 ng/mL human or mouse TNF-α or 100 ng/mL LPS as indicated. MLN4924 was dissolved as established (81) and used at a concentration of 500 nmol/L for 2-4 h in all experiments.
Analysis of NF-κB p65 Activity and ELISA. NF-κB p65 DNA binding activity was quantified by using the TransAM NF-κB p65 ELISA (Active Motif) according to the supplier's instructions. NF-κB reporter assays were performed by transfecting an NF-κB luciferase reporter and a β-gal expression construct. After 48 h, cells were exposed to MLN4924 or DMSO control for 16 h, followed by stimulation with TNF-α. Luciferase and β-gal activities were assessed by using Bright-Glo luciferase system and β-gal enzyme assay (Promega). Cytokine levels of TNF-α, IL-10, IL-12p70, and MIF in serum and/or cell culture supernatant were measured by using commercially available kits.
Macrophage Proliferation and Adhesion Under Laminar Flow. Macrophage proliferation was quantified by using a BrdU-based colorimetric immunoassay (Roche Diagnostics). Adhesion of Calcein-AM-labeled THP1 monocytes on confluent HUVEC monolayers, pretreated with MLN4924 or DMSO control and stimulated with 20 ng/mL human TNF-α as indicated, was quantified in parallel wall chambers under flow (1.5 dyn/cm 2 , 4 min) (3).
Quantitative Real-Time PCR and Western Blot Analysis. Quantitative real-time PCR analysis was performed with primers as listed in SI Appendix. miRs were isolated by using the miRVana miRNA isolation kit (Thermo Fisher). Quantitative PCR was performed by using the TaqMan MicroRNA Reverse Transcription Kit, TaqMan Gene Expression Master Mix, and predeveloped TaqMan miR assays (5p strands; all Thermo Fisher). U6 snRNA was used as reference miRNA. Total cell lysates were prepared by lysis in RIPA buffer (Pierce) containing protease and phosphatase inhibitors or alternatively in 1× NuPAGE-LDSsample buffer containing 1 mmol/L DTT. Nuclear extracts were isolated by using a subcellular fractionation kit according to the manufacturer's protocol (Active Motif) or as described previously (82) .
Statistical Analysis. Statistical analysis was performed by using GraphPad Prism software (version 5; GraphPad). Data are represented as means ± SD. After testing for normality, data were analyzed by two-tailed Student's t test or Mann-Whitney test, one-way ANOVA with Newman-Keuls or Dunn's posttest, or two-way ANOVA with Bonferroni posttest as appropriate. Differences with P < 0.05 were considered to be statistically significant.
